Logo image of SNSE

SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SNSE - US81728A2078 - Common Stock

9.53 USD
+0.67 (+7.56%)
Last: 12/22/2025, 4:30:02 PM
Fundamental Rating

2

Overall SNSE gets a fundamental rating of 2 out of 10. We evaluated SNSE against 530 industry peers in the Biotechnology industry. SNSE has a great financial health rating, but its profitability evaluates not so good. SNSE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SNSE had negative earnings in the past year.
In the past year SNSE has reported a negative cash flow from operations.
SNSE had negative earnings in each of the past 5 years.
In the past 5 years SNSE always reported negative operating cash flow.
SNSE Yearly Net Income VS EBIT VS OCF VS FCFSNSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

SNSE has a worse Return On Assets (-87.50%) than 71.89% of its industry peers.
SNSE has a Return On Equity of -104.92%. This is comparable to the rest of the industry: SNSE outperforms 45.09% of its industry peers.
Industry RankSector Rank
ROA -87.5%
ROE -104.92%
ROIC N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
SNSE Yearly ROA, ROE, ROICSNSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

SNSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNSE Yearly Profit, Operating, Gross MarginsSNSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

SNSE has more shares outstanding than it did 1 year ago.
SNSE has less shares outstanding than it did 5 years ago.
The debt/assets ratio for SNSE has been reduced compared to a year ago.
SNSE Yearly Shares OutstandingSNSE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SNSE Yearly Total Debt VS Total AssetsSNSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -14.69, we must say that SNSE is in the distress zone and has some risk of bankruptcy.
SNSE has a Altman-Z score of -14.69. This is amonst the worse of the industry: SNSE underperforms 80.00% of its industry peers.
There is no outstanding debt for SNSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.69
ROIC/WACCN/A
WACCN/A
SNSE Yearly LT Debt VS Equity VS FCFSNSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.81 indicates that SNSE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.81, SNSE is in the better half of the industry, outperforming 60.94% of the companies in the same industry.
A Quick Ratio of 5.81 indicates that SNSE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.81, SNSE is in the better half of the industry, outperforming 62.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.81
Quick Ratio 5.81
SNSE Yearly Current Assets VS Current LiabilitesSNSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

SNSE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.62%, which is quite good.
EPS 1Y (TTM)19.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SNSE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.36% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.93%
EPS Next 2Y25.37%
EPS Next 3Y13.75%
EPS Next 5Y8.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNSE Yearly Revenue VS EstimatesSNSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M
SNSE Yearly EPS VS EstimatesSNSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SNSE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNSE Price Earnings VS Forward Price EarningsSNSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNSE Per share dataSNSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

SNSE's earnings are expected to grow with 13.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.37%
EPS Next 3Y13.75%

More info and screens

0

5. Dividend

5.1 Amount

SNSE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SENSEI BIOTHERAPEUTICS INC

NASDAQ:SNSE (12/22/2025, 4:30:02 PM)

9.53

+0.67 (+7.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-26 2026-03-26/amc
Inst Owners3.95%
Inst Owner Change-45.14%
Ins Owners2.23%
Ins Owner Change-0.27%
Market Cap12.01M
Revenue(TTM)N/A
Net Income(TTM)-24.14M
Analysts82.5
Price Target33.15 (247.85%)
Short Float %0.11%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.6%
Min EPS beat(2)13.65%
Max EPS beat(2)31.55%
EPS beat(4)2
Avg EPS beat(4)4.21%
Min EPS beat(4)-18.53%
Max EPS beat(4)31.55%
EPS beat(8)5
Avg EPS beat(8)2.63%
EPS beat(12)9
Avg EPS beat(12)4.93%
EPS beat(16)11
Avg EPS beat(16)3.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.55%
EPS NY rev (1m)-5.47%
EPS NY rev (3m)7.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)-19.13
EYN/A
EPS(NY)-10.28
Fwd EYN/A
FCF(TTM)-17.78
FCFYN/A
OCF(TTM)-17.76
OCFYN/A
SpS0
BVpS18.26
TBVpS18.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.5%
ROE -104.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.81
Quick Ratio 5.81
Altman-Z -14.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.02%
Cap/Depr(5y)183.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.59%
EPS Next Y20.93%
EPS Next 2Y25.37%
EPS Next 3Y13.75%
EPS Next 5Y8.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.44%
EBIT Next 3Y0.09%
EBIT Next 5YN/A
FCF growth 1Y37.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.85%
OCF growth 3YN/A
OCF growth 5YN/A

SENSEI BIOTHERAPEUTICS INC / SNSE FAQ

Can you provide the ChartMill fundamental rating for SENSEI BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to SNSE.


What is the valuation status for SNSE stock?

ChartMill assigns a valuation rating of 0 / 10 to SENSEI BIOTHERAPEUTICS INC (SNSE). This can be considered as Overvalued.


How profitable is SENSEI BIOTHERAPEUTICS INC (SNSE) stock?

SENSEI BIOTHERAPEUTICS INC (SNSE) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SENSEI BIOTHERAPEUTICS INC?

The Earnings per Share (EPS) of SENSEI BIOTHERAPEUTICS INC (SNSE) is expected to grow by 20.93% in the next year.